MOTS-C is the first peptide known to be encoded by mitochondrial DNA. Its discovery has reshaped how researchers think about cellular aging and metabolic regulation.
In 2015, researchers at USC published a paper in *Cell Metabolism* that quietly changed the way scientists think about mitochondria. They had identified a new peptide — MOTS-C — encoded not by nuclear DNA, but by the mitochondrial genome itself. It was the first mitochondria-derived peptide of its kind, and its biology turned out to be far more interesting than anyone anticipated.
Every peptide researchers had studied before MOTS-C was encoded by nuclear DNA — the genome housed in the cell's nucleus. Mitochondria have their own small, circular genome (mtDNA), containing only 37 genes — but those 37 genes are extraordinarily ancient and highly conserved across species.
MOTS-C comes from a short open reading frame within the 12S ribosomal RNA gene of the mitochondrial genome. The fact that this region produces a biologically active peptide was entirely unexpected. Even more surprising was what that peptide does: it functions as a metabolic hormone, traveling from the mitochondria through the cytoplasm and into the nucleus to regulate gene expression — mitochondria talking directly to the nucleus in a language researchers are only beginning to understand.
MOTS-C's primary cellular mechanism involves activation of AMPK — AMP-activated protein kinase, the enzyme often described as the cell's "master metabolic switch." AMPK is activated by low-energy states (low ATP:AMP ratio) and responds by suppressing energy-consuming processes and activating energy-generating ones: fatty acid oxidation, glucose uptake, and mitochondrial biogenesis.
MOTS-C activates AMPK in skeletal muscle, creating a metabolic environment that promotes: - Glucose uptake independent of insulin - Fat oxidation over glucose oxidation - Reduced ectopic fat deposition in muscle and liver - Improved mitochondrial efficiency
In obese mouse models, MOTS-C injection reversed diet-induced insulin resistance — a finding that generated significant interest in its therapeutic potential.
One of the most important findings from the original 2015 research and subsequent studies: circulating MOTS-C levels decline significantly with age in humans. Plasma MOTS-C is measurably lower in older individuals compared to younger ones, with the decline tracking closely to the metabolic changes we associate with aging — reduced insulin sensitivity, increased fat deposition, lower exercise capacity, and declining mitochondrial function.
This raises a compelling hypothesis: is declining MOTS-C a contributing mechanism of metabolic aging? Research continues, but supplementation studies in aged mice have shown improvements in physical performance and, in some models, extended median lifespan — results that have placed MOTS-C firmly in the longevity research conversation alongside Epitalon and Thymosin Alpha-1.
Perhaps MOTS-C's most surprising property is its ability to translocate to the nucleus under metabolic stress conditions. Once in the nucleus, it directly binds to regulatory DNA sequences and influences gene transcription — particularly genes involved in antioxidant defense, inflammatory suppression, and metabolic adaptation.
This nuclear signaling function is virtually unprecedented for a mitochondria-derived molecule and suggests MOTS-C is doing something more sophisticated than simple enzyme activation: it is acting as a sensor and messenger that physically carries information from the mitochondrial energy state to the nuclear gene expression machinery.
Interestingly, circulating MOTS-C levels rise with acute exercise in humans — suggesting it may be part of the molecular explanation for exercise's metabolic benefits. Research exploring MOTS-C as an "exercise mimetic" (a compound that partially recapitulates exercise's metabolic effects) is ongoing, with AMPK activation as the common thread.
MOTS-C research is still in its early phases relative to more established compounds like TB-500 or CJC-1295. But the quality of the science — published in Cell Metabolism, backed by USC and Harvard-affiliated researchers, with clear molecular mechanisms — places it in a different category than many speculative longevity compounds.
For researchers studying metabolic aging, insulin resistance, mitochondrial biology, or exercise physiology, MOTS-C represents a compound with a genuinely novel mechanism and credible preclinical support.
*Corevanta's MOTS-C is provided in 10mg lyophilized vials at ≥99% purity, verified by HPLC and LC-MS. For research purposes only.*
Research compounds discussed in this article
All compounds discussed in this article are sold by Corevanta for laboratory research purposes only. They are not approved drugs, not dietary supplements, and are not intended for human consumption or therapeutic use. Always comply with applicable local regulations.